Biogen Idec invests together with Eisai in BioArctic´s antibody BAN2401 for treatment of Alzheimer´s disease

AGREEMENT TO ENHANCE R&D CAPABILITIES AIMED AT CREATING NEW THERAPIES TO SUPPRESS ALZHEIMER’S DISEASE PROGRESSION

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize next-generation therapies for Alzheimer’s disease (AD). The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two clinical candidates: E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A?) antibody licensed from BioArctic Neuroscience AB. These candidates have the potential to reduce toxic A? protofibrils and plaques in the brains of patients with AD a potentially improving symptoms and suppressing disease progression. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-A? antibody BIIB037 and an anti-tau monoclonal antibody.

BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between Eisai and BioArctic Neuroscience AB to identify a potential immunotherapy for AD. BAN2401 is believed to selectively bind to, neutralize and eliminate soluble, toxic A? protofibrils that are thought to contribute to the neurodegenerative process in AD. As such, BAN2401 has the potential to have an immunomodulatory effect that may suppress the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic Neuroscience AB in December 2007. BioArctic Neuroscience AB retained the marketing rights of BAN2401 in the Nordic countries. Currently, the compound is undergoing Phase IIb clinical trials.

“We see this new collaboration between Eisai and Biogen Idec as a very good way to enable further development of BAN2401 in a beneficial way and we hope that it will slow down disease progression and create a future benefit for Alzheimer patients”, says Gunilla Osswald CEO of BioArctic Neuroscience AB.”

Press release by Eisai:
http://www.eisai.com/news/news201410.html

Press release by Biogen Idec:
http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2292&M=NewsV2&PID=61997